Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 18c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of ($1.17), $0.18 worse than the analyst estimate of ($0.99). Revenue for the quarter came in at $110.4 million versus the consensus estimate of $99.38 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• DeFi Technologies (DEFT) PT Lowered to $1 at Benchmark Following Q2 Miss
• GLJ Research on Sell Rated Tesla (TSLA): 'We now see FSD as the main reason TSLA’s stock will bleed lower this year'